Structure Guided AI Drug Design at the Protein/RNA Interface
Azor Biotek has developed an AI-guided suite to generate novel small molecule entities targeting biological complexes at RNA/protein interfaces. Protein-targeting AI is common — targeting RNA is presently unachievable by heuristic means alone. The limited community of researchers targeting RNA with small molecules is almost exclusively focused on targeting naked, labile RNA solution structures. In contrast, our novel software suite (systems biology target analysis, library generation, virtual screening, and hit optimization) targets stabilized RNA/protein interfaces.
The current market for RNA-targeted small molecules is valued at well over $100-billion, with only four established drug targets — each of them in biological complex with proteins. Azor Biotek's innovative approach allows for the design of novel molecules to target any RNA, over- or underexpressed — opening many previously inaccessible avenues for therapeutic development. Every disease indication has multiple unexploited RNA drug targets we would be happy to deconvolute and explore with you.
Early screening in zebrafish selects for therapeutics with high bioactivity, and allows for in vivo quantification of concrete physiological hallmarks while providing approximations of the effective dose, blood brain barrier penetrance, toxicity and other off-target effects.
miR-29 enhancing processivity clamp assets are being developed as epithelial transitioning, anti-angiogenic anti-metastatics.
Financing sought for IND enabling rodent studies in 2024.
Copyright © 2022 Azor Biotek - All Rights Reserved.